Condition: Neurogenic Bladder · Sponsor: Medstar Health Research Institute
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
This description comes directly from the study's public registry record.
Amanda K Rounds, PhD · 202-877-1591 · Amanda.K.Rounds@medstar.net
Inger H Ljungberg · 202-877-1694 · Inger.H.Ljungberg@medstar.net
Always discuss trial participation with your own doctor first.
| MedStar National Rehabilitation Hospital | Washington D.C., District of Columbia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04323735